Collection of Blood From Patients With Prostate Cancer
Conditions
Prostatic Neoplasms
Conditions: official terms
Prostatic Neoplasms
Conditions: Keywords
Blood, Prostate Cancer, Genotyping
Study Type
Observational
Study Phase
N/A
Study Design
Time Perspective: Cross-Sectional
Overall Status
Recruiting
Summary
Background:

- It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role.

- Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene.

- Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others.

Objectives:

-To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state.

Eligibility:

-All patients participating in NCI prostate cancer protocols.

Design:

- Patients with prostate cancer are evaluated in the NCI s Medical Oncology Clinic.

- Blood samples are collected at the initial visit or at follow-up visits.

- DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines.

- Gene variations are correlated with prostate cancer prognosis and prognostic indicators.
Detailed Description
Objectives:

To obtain blood samples from patients with prostate cancer for genotyping analyses.

Eligibility:

All patients seen in the NCI prostate cancer clinic are eligible.

Design:

Patients with a prior diagnosis of prostate cancer will be evaluated in the Medical Oncology Clinic, NCI. Blood samples may be collected at the initial visit or at follow-up visits. Genomic DNA and white blood cells will each be extracted from these samples to be utilized for genotyping and establishment of individual cell lines. Genetic variance will be correlated with prostate cancer prognosis (i.e. time from diagnosis to death) and prognostic indicators (i.e. histological tumor grade). Healthy controls will not be compared and no correlations will be made with prostate cancer susceptibility.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Male
Criteria: - INCLUSION CRITERIA:

Patients 18 years of age and older are eligible.

Patients with a diagnosis of prostate cancer are eligible.

EXCLUSION CRITERIA:

Children are not eligible.
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Status: Recruiting
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office - (888) NCI-1937
Start Date
February 2007
Sponsors
National Cancer Institute (NCI)
Source
National Institutes of Health Clinical Center (CC)
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page